[HTML][HTML] Regulation of intrinsic functions of PD-L1 by post-translational modification in tumors
NT Nihira, Y Miki - Frontiers in Oncology, 2022 - frontiersin.org
Tumor cells are eliminated by the immune system, including T lymphocytes and natural killer
cells; however, many types of tumor cells acquire the immune tolerance by inhibiting T-cell …
cells; however, many types of tumor cells acquire the immune tolerance by inhibiting T-cell …
[HTML][HTML] Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
C Feng, L Zhang, X Chang, D Qin, T Zhang - Frontiers in Immunology, 2023 - frontiersin.org
The immune checkpoint molecules programmed cell death receptor 1 (PD-1) and
programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor …
programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor …
[HTML][HTML] A snapshot of the PD-1/PD-L1 pathway
Cancer cells can evade the attack from host immune systems via hijacking the regulatory
circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by …
circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by …
[HTML][HTML] Mechanisms controlling PD-L1 expression in cancer
The engagement of programmed cell death protein 1 (PD-1; encoded by the PDCD1 gene)
receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; …
receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; …
[HTML][HTML] Regulation of PD-L1: emerging routes for targeting tumor immune evasion
Y Wang, H Wang, H Yao, C Li, JY Fang… - Frontiers in …, 2018 - frontiersin.org
Immune checkpoint blockade therapies (ICBTs) targeting programmed cell death 1 (PD-1)
and its ligand programmed death ligand-1 (PD-L1/B7-H1/CD274) have exhibited …
and its ligand programmed death ligand-1 (PD-L1/B7-H1/CD274) have exhibited …
[HTML][HTML] Current insight into the regulation of PD-L1 in cancer
Z Liu, X Yu, L Xu, Y Li, C Zeng - Experimental hematology & oncology, 2022 - Springer
The molecular mechanisms underlying cancer immune escape are a core topic in cancer
immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by …
immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by …
[HTML][HTML] Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
[HTML][HTML] Regulatory mechanisms of PD-1/PD-L1 in cancers
X Lin, K Kang, P Chen, Z Zeng, G Li, W Xiong, M Yi… - Molecular Cancer, 2024 - Springer
Immune evasion contributes to cancer growth and progression. Cancer cells have the ability
to activate different immune checkpoint pathways that harbor immunosuppressive functions …
to activate different immune checkpoint pathways that harbor immunosuppressive functions …
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy
ZY Dong, SP Wu, RQ Liao, SM Huang, YL Wu - Tumor Biology, 2016 - Springer
Programmed cell death protein-1 (PD-1) and ligand (PD-L1) provide an important escape
mechanism from immune attack, and blockade therapy of these proteins show promising …
mechanism from immune attack, and blockade therapy of these proteins show promising …
[HTML][HTML] Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
M Wu, Q Huang, Y Xie, X Wu, H Ma, Y Zhang… - Journal of hematology & …, 2022 - Springer
Immune checkpoint molecules are promising anticancer targets, among which therapeutic
antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment …
antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment …